{
  "trial_id": "NCT02215967",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, clinical performance status (ECOG), BCMA expression on malignant plasma cells, bone marrow plasma cell percentage, number of prior treatment regimens, measurable multiple myeloma criteria (serum M-protein, urine M-protein, serum free light chain assay, biopsy-proven plasmacytoma), disease category (progressive disease or relapse from complete remission), absolute neutrophil count, platelet count, hemoglobin level, plasma cells in peripheral blood leukocytes, serum alanine transaminase (ALT) level, serum aspartate transaminase (AST) level, serum creatinine level, total bilirubin level, cardiac ejection fraction, presence of hemodynamically significant pericardial effusion, history of myocardial infarction, presence of active infections, presence of active autoimmune diseases, history of allogeneic stem cell transplantation, presence of CNS metastases or symptomatic CNS involvement.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "clinical performance status (ECOG)",
        "BCMA expression on malignant plasma cells",
        "bone marrow plasma cell percentage",
        "number of prior treatment regimens",
        "measurable multiple myeloma criteria (serum M-protein, urine M-protein, serum free light chain assay, biopsy-proven plasmacytoma)",
        "disease category (progressive disease or relapse from complete remission)",
        "absolute neutrophil count",
        "platelet count",
        "hemoglobin level",
        "plasma cells in peripheral blood leukocytes",
        "serum alanine transaminase (ALT) level",
        "serum aspartate transaminase (AST) level",
        "serum creatinine level",
        "total bilirubin level",
        "cardiac ejection fraction",
        "presence of hemodynamically significant pericardial effusion",
        "history of myocardial infarction",
        "presence of active infections",
        "presence of active autoimmune diseases",
        "history of allogeneic stem cell transplantation",
        "presence of CNS metastases or symptomatic CNS involvement"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Previous Treatment Regimens, Bone Marrow Plasma Cell Percentage, Serum M-protein, Urine M-protein, Serum Free Light Chain (FLC) Level, Hemoglobin, Platelet Count, Absolute Neutrophil Count, Serum Creatinine, Serum Alanine Transaminase (ALT), Serum Aspartate Transaminase (AST), Total Bilirubin, Cardiac Ejection Fraction, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Previous Treatment Regimens",
        "Bone Marrow Plasma Cell Percentage",
        "Serum M-protein",
        "Urine M-protein",
        "Serum Free Light Chain (FLC) Level",
        "Hemoglobin",
        "Platelet Count",
        "Absolute Neutrophil Count",
        "Serum Creatinine",
        "Serum Alanine Transaminase (ALT)",
        "Serum Aspartate Transaminase (AST)",
        "Total Bilirubin",
        "Cardiac Ejection Fraction"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Eastern Cooperative Oncology Group (ECOG) Performance Status, Multiple Myeloma Disease Status, Prior Therapies, Bone Marrow Plasma Cell Percentage, Serum M-Protein, Urine M-Protein, Serum Free Light Chain, Bone Marrow Biopsy Results, Absolute Neutrophil Count, Platelet Count, Hemoglobin, Serum Alanine Transaminase, Serum Aspartate Transaminase, Serum Creatinine, Total Bilirubin, Cardiac Ejection Fraction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "Multiple Myeloma Disease Status",
        "Prior Therapies",
        "Bone Marrow Plasma Cell Percentage",
        "Serum M-Protein",
        "Urine M-Protein",
        "Serum Free Light Chain",
        "Bone Marrow Biopsy Results",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Hemoglobin",
        "Serum Alanine Transaminase",
        "Serum Aspartate Transaminase",
        "Serum Creatinine",
        "Total Bilirubin",
        "Cardiac Ejection Fraction"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, multiple myeloma disease category (progressive disease or relapse from complete remission), number of prior treatment regimens, serum M-protein level, urine M-protein level, serum free light chain (FLC) level, bone marrow plasma cell percentage, presence of plasmacytoma, absolute neutrophil count, platelet count, hemoglobin level, serum alanine transaminase (ALT) level, serum aspartate transaminase (AST) level, serum creatinine level, total bilirubin level, cardiac ejection fraction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "body mass index (BMI)",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "multiple myeloma disease category (progressive disease or relapse from complete remission)",
        "number of prior treatment regimens",
        "serum M-protein level",
        "urine M-protein level",
        "serum free light chain (FLC) level",
        "bone marrow plasma cell percentage",
        "presence of plasmacytoma",
        "absolute neutrophil count",
        "platelet count",
        "hemoglobin level",
        "serum alanine transaminase (ALT) level",
        "serum aspartate transaminase (AST) level",
        "serum creatinine level",
        "total bilirubin level",
        "cardiac ejection fraction"
      ]
    }
  }
}